| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(2 years from now) | |
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(2 years from now) | |
Vocabria is owned by Viiv Hlthcare.
Vocabria contains Cabotegravir Sodium.
Vocabria has a total of 2 drug patents out of which 0 drug patents have expired.
Vocabria was authorised for market use on 21 January, 2021.
Vocabria is available in tablet;oral dosage forms.
Vocabria can be used as treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg.
Drug patent challenges can be filed against Vocabria from 21 January, 2025.
The generics of Vocabria are possible to be released after 28 April, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
| New Patient Population(NPP) | Mar 29, 2025 |
| M(M-273) | Jan 31, 2025 |
Drugs and Companies using CABOTEGRAVIR SODIUM ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg
Dosage: TABLET;ORAL
VOCABRIA family patents
